ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SBC vs STLN // DIVIDEND YIELD & FCF PAYOUT SAFETY

SBC Medical Group Holdings Incorporated (NASDAQ) VS. Starling Oncology Inc. (NASDAQ) • 15-METRIC TALLY: SBC 6 — STLN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBC VS. STLN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SBC STLN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 63.10% -35.00% +98.10 SBC /roic <GO>
EV/EBITDA & P/E Valuation 6.1x — — TIE /valuation <GO>
Free Cash Flow Yield 3.98% -4.10% +8.08 SBC /fcf-yield <GO>
Operating Margin 38.90% -7.20% +46.10 SBC /operating-margins <GO>
Net Profit Margin 29.40% 68.00% -38.60 STLN /net-margins <GO>
Revenue Growth (YoY) -15.50% 27.80% -43.30 STLN /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.46 2.58 +2.88 SBC /balance-sheet <GO>
Piotroski F-Score Quality 6/9 3/9 +3.00 SBC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.8 49.5 +2.31 SBC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $585.2M $677.7M -$92.5M STLN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SBC REV STLN REV SBC GROSS % STLN GROSS % SBC FCF STLN FCF
FY 2025 $173.6M $502.7M 73.3% — $23.3M -$27.8M
FY 2024 $205.4M $393.4M 76.0% — $18.0M -$30.3M
FY 2023 $193.5M $324.2M — — $50.7M -$36.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBC // BETA —
STLN // BETA —